Absorica Ld is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 2 US drug patents filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 04, 2035. Details of Absorica Ld's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9700535 | Oral pharmaceutical composition of isotretinoin |
Aug, 2035
(8 years from now) | Active |
| US9750711 | Low dose oral pharmaceutical composition of isotretinoin |
May, 2035
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Absorica Ld's patents.
Latest Legal Activities on Absorica Ld's Patents
Given below is the list of recent legal activities going on the following patents of Absorica Ld.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Mar, 2025 | US9750711 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jan, 2025 | US9700535 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Mar, 2021 | US9750711 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2021 | US9700535 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 31 Oct, 2018 | US9750711 |
| Email Notification
Critical | 31 Oct, 2018 | US9700535 |
| Change in Power of Attorney (May Include Associate POA)
Critical | 31 Oct, 2018 | US9700535 |
| Email Notification
Critical | 31 Oct, 2018 | US9750711 |
| Correspondence Address Change
Critical | 30 Oct, 2018 | US9750711 |
| Correspondence Address Change
Critical | 30 Oct, 2018 | US9700535 |
US patents provide insights into the exclusivity only within the United States, but
Absorica Ld is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Absorica Ld's family patents as well as insights into
ongoing legal events
on those patents.
Absorica Ld's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Absorica Ld:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma | National Cancer Institute (NCI) | NA | ACTIVE NOT RECRUITING
(Sep 1, 2026) | PHASE1 |
| Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma | National Cancer Institute (NCI) | NA | COMPLETED
(May 1, 2026) | PHASE3 |
| Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis | Zagazig University | NA | RECRUITING
(Apr 1, 2026) | PHASE1 |
| Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm | University of Nebraska | NA | ENROLLING BY INVITATION
(Apr 1, 2026) | PHASE2 |
| Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | New Approaches to Neuroblastoma Therapy Consortium | NA | ACTIVE NOT RECRUITING
(Mar 1, 2026) | PHASE1 |
Generic Launch
Generic Release Date:
Absorica Ld's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 04, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Absorica Ld Generic API suppliers:
Isotretinoin is the generic name for the brand Absorica Ld. 10 different companies have already filed for the generic of Absorica Ld, with Zydus Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Absorica Ld's generic
Alternative Brands for Absorica Ld
There are several other brand drugs using the same active ingredient (Isotretinoin) as Absorica Ld. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Sun Pharm Inds Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Isotretinoin, Absorica Ld's active ingredient. Check the complete list of approved generic manufacturers for Absorica Ld
About Absorica Ld
Absorica Ld is a drug owned by Sun Pharmaceutical Industries Ltd. Absorica Ld uses Isotretinoin as an active ingredient. Absorica Ld was launched by Sun Pharma in 2019.
Approval Date:
Absorica Ld was approved by FDA for market use on 05 November, 2019.
Active Ingredient:
Absorica Ld uses Isotretinoin as the active ingredient. Check out other Drugs and Companies using Isotretinoin ingredient
Dosage:
Absorica Ld is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 8MG | CAPSULE | Prescription | ORAL |
| 28MG | CAPSULE | Discontinued | ORAL |
| 16MG | CAPSULE | Prescription | ORAL |
| 32MG | CAPSULE | Prescription | ORAL |
| 20MG | CAPSULE | Discontinued | ORAL |
| 24MG | CAPSULE | Prescription | ORAL |